Search

Displaying results 4301 - 4310 of 7452 in total
  1. Drug

    Dalcetrapib

    go.drugbank.com/drugs/DB12181
    Investigational

    Dalcetrapib is under investigation for the treatment of Acute Coronary Syndrome.

  2. Drug

    VP-14637

    go.drugbank.com/drugs/DB12195
    Investigational

    MDT-637 has been investigated for the treatment of Drug Safety.

  3. Drug

    Tozadenant

    go.drugbank.com/drugs/DB12203
    Investigational

    Tozadenant has been investigated for the basic science of Cocaine Dependence.

  4. Drug

    N-acetylmannosamine

    go.drugbank.com/drugs/DB12536
    Investigational

    N-acetylmannosamine is under investigation for the other of GNE Myopathy.

  5. Drug

    Spiradoline

    go.drugbank.com/drugs/DB12704
    Investigational

    Spiradoline has been investigated for the basic science of Bipolar Depression.

  6. Drug

    YMI024

    go.drugbank.com/drugs/DB32602
    Experimental

    YMI024 is a drug being investigated for inflammation-driven diseases.[L56081]

  7. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  8. Drug

    Vintafolide

    go.drugbank.com/drugs/DB05168
    Investigational

    Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.

  9. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  10. Drug

    Talniflumate

    go.drugbank.com/drugs/DB09295
    Investigational

    Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this … Talniflumate has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan) [L1405].